Thursday, November 04, 2021 2:55:51 PM
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL
https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
Recent IOBT News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 10:22:46 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 10:06:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 09:53:41 PM
- IO Biotech Provides Corporate Update • GlobeNewswire Inc. • 01/30/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 11:05:41 AM
- IO Biotech Announces Exploration of Strategic Alternatives • GlobeNewswire Inc. • 01/21/2026 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 10:18:23 PM
- IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications • GlobeNewswire Inc. • 12/15/2025 09:05:00 PM
- IO Biotech Announces Participation in Upcoming December Investor Conferences • GlobeNewswire Inc. • 11/26/2025 03:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2025 09:44:15 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • InvestorsHub NewsWire • 11/20/2025 02:00:00 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • GlobeNewswire Inc. • 11/20/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 11:30:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 01:10:14 PM
- IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 11/14/2025 01:05:00 PM
- IO Biotech Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/12/2025 01:30:00 PM
- IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) • GlobeNewswire Inc. • 11/07/2025 02:00:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • InvestorsHub NewsWire • 10/27/2025 01:00:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • PR Newswire (US) • 10/27/2025 12:30:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • PR Newswire (Canada) • 10/27/2025 12:30:00 PM
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 • GlobeNewswire Inc. • 10/20/2025 06:30:00 AM
- Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion • PR Newswire (Canada) • 10/07/2025 01:00:00 PM
